S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:CLSD

Clearside Biomedical - CLSD Stock Forecast, Price & News

$0.96
0.00 (-0.31%)
(As of 03/30/2023 04:32 PM ET)
Add
Compare
Today's Range
$0.95
$0.98
50-Day Range
$0.93
$1.54
52-Week Range
$0.90
$2.54
Volume
87,361 shs
Average Volume
202,576 shs
Market Capitalization
$58.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Clearside Biomedical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
531.6% Upside
$6.00 Price Target
Short Interest
Healthy
0.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Clearside Biomedical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$73,943 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

724th out of 999 stocks

Pharmaceutical Preparations Industry

358th out of 489 stocks


CLSD stock logo

About Clearside Biomedical (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Wedbush Reaffirms Their Buy Rating on Clearside Biomedical (CLSD)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Clearside Biomedical Announces Leadership Team Update
Analyst Expectations for Clearside Biomedical's Future
Clearside Biomedical
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Company Calendar

Last Earnings
11/10/2021
Today
3/30/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSD
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+525.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-32,950,000.00
Net Margins
-2,482.82%
Pretax Margin
-2,482.82%

Debt

Sales & Book Value

Annual Sales
$1.33 million
Book Value
$0.18 per share

Miscellaneous

Free Float
54,000,000
Market Cap
$58.91 million
Optionable
Optionable
Beta
1.95

Key Executives

  • George M. LasezkayGeorge M. Lasezkay
    President, Chief Executive Officer & Director
  • Charles A. DeignanCharles A. Deignan
    Chief Financial Officer
  • Rafael V. Andino
    Senior VP-Engineering & Manufacturing
  • Susan L. Coultas
    Chief Clinical Officer
  • Leslie B. Zacks
    Secretary & Chief Compliance Officer













CLSD Stock - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price forecast for 2023?

4 equities research analysts have issued 1-year price targets for Clearside Biomedical's shares. Their CLSD share price forecasts range from $4.00 to $8.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 527.0% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2023?

Clearside Biomedical's stock was trading at $1.12 at the beginning of 2023. Since then, CLSD stock has decreased by 14.6% and is now trading at $0.9570.
View the best growth stocks for 2023 here
.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a increase in short interest in March. As of March 15th, there was short interest totaling 351,200 shares, an increase of 8.7% from the February 28th total of 323,100 shares. Based on an average trading volume of 237,900 shares, the short-interest ratio is presently 1.5 days. Currently, 0.7% of the company's stock are sold short.
View Clearside Biomedical's Short Interest
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our CLSD earnings forecast
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its earnings results on Wednesday, November, 10th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm earned $3.07 million during the quarter, compared to the consensus estimate of $3.32 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 153.06% and a negative net margin of 2,482.82%. During the same quarter in the previous year, the business earned ($0.05) earnings per share.

What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.98%), Johnson & Johnson (0.28%), Assenagon Asset Management S.A. (0.28%), Two Sigma Investments LP (0.17%), Northeast Financial Consultants Inc (0.14%) and Hamilton Lane Advisors LLC (0.11%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $0.96.

How much money does Clearside Biomedical make?

Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $58.72 million and generates $1.33 million in revenue each year. The company earns $-32,950,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033.

This page (NASDAQ:CLSD) was last updated on 3/30/2023 by MarketBeat.com Staff